Derbyshire-based N4 Pharma has launched a broker offer to raise a maximum of £1 million.
It is initially expected that £0.25 million will be raised in the offer, though if oversubscribed it may be extended.
The issue price of the broker offer is 2 pence per new ordinary share.
Turner Pope Investments (TPI) Limited is agent for the company.
N4 Pharma is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.